Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Conditions
Advanced Solid Tumor
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of California, Los Angeles, Santa Monica, California, United States
Contact: Study coordinator (Lee Rosen, MD)H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida, United States
Contact: Study coordinator (Heather Han, MD)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Geoffrey Shapiro, MD)Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
Contact: Study coordinator (Sagar Sardesai, MD)UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (Sarah Taylor, MD)Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact: Study coordinator (Amit Oza, MD)Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
Contact: Study coordinator (Diane Provencher, MD)
Study leads
Jason Huang, MD
Study Director
Senhwa Biosciences